The role of clofarabine in hematologic and solid malignancies - Development of a next-generation nucleoside analog

Cancer

Volumn 103, Issue 10, 2005, Pages 1985-1995

  Faderl, Stefan ^a   Gandhi, Varsha ^a   Keating, Michael J ^a   Jeha, Sima ^b   Plunkett, William ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute leukemias; Clofarabine; Nucleoside analogs; Solid tumors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CLADRIBINE; CLOFARABINE; CYTARABINE; DEOXYCYTIDINE KINASE; DNA; DNA POLYMERASE; FLUDARABINE; HYDROXYUREA; IDARUBICIN; NUCLEOSIDE ANALOG; RIBONUCLEOTIDE REDUCTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; ENZYME INHIBITION; EVALUATION; FATIGUE; FEVER; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; LIVER DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LIVER TRANSAMINASE ELEVATION; LYMPHOPROLIFERATIVE DISEASE; MEDICAL LITERATURE; MEDLINE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NONHUMAN; PALMOPLANTAR DYSESTHESIA; PARANASAL SINUS CONGESTION; PARANASAL SINUS DISEASE; PRIORITY JOURNAL; PUBLICATION; RASH; REVIEW; SKIN TOXICITY; SOLID TUMOR; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; TRANSAMINITIS; VOMITING;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CHILD; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS;

EID: 18044390106     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21005     Document Type: Review

References (48)

1. Elion GB. The purine path to chemotherapy. Science. 1989;244:41-47.
2. Heidelberger C, Danenberg PV, Moran RG. Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol. 1983;54:58-119.
3. Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analog-induced apoptosis in leukemia cells. Clin Cancer Res. 1995;1:1005-1013.
4. Grem JL, Takimoto CH, Multani P, et al. Antimetabolites. Cancer Chemother Biol Response Modif. 1999;18:1-38.
5. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induced programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000;96:3537-3543.
6. Johnson SA. Clinical pharmcokinetixs of nucleoside analogues: focus on haematological malignancies. Clin Pharmacokinet. 2000;39:5-26.
7. Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002;20:37-58.
8. Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res. 1998;72:197-233.
9. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(Suppl 11):3-10.
10. Pott-Hoeck C, Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol. 1995;6:421-433.
11. Warrell RP Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4:74-79.
12. Crews KR, Gandhi V, Srivastava DK, et al. Evaluation of continuous infusion versus bolus infusion of cytarabine in combination with cladribine in pediatric acute myeloid leukemia: an interim analysis. J Clin Oncol. 2002;20:4217-4224.
13. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, et al. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D- arabinofuranosyladenine. J Med Chem. 1992;35:397-401.
14. Parker WB, Allan PW, Hassan AE, et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 2003;10:23-29.
15. Avramis VI, Plunkett W. 2-Fluoro-ATP: a toxic metabolite of 9-β-D-arabinofuranosyl-2-fluoroadenine. Biochem Biophys Res Commun. 1983;113:35-43.
16. Avramis VI, Plunkett W. Metabolism of 9-β-D-arabinofuranosyl-2- fluoroadenine 5′-phosphate by mice bearing P388 leukemia. Cancer Drug Delivery. 1983;1:1-10.
17. Huang P, Plunkett W. Phosphorolytic cleavage of 2-fluoroadenine from 9-b-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli: a pathway for 2-fluoro-ATP production. Biochem Pharm. 1987;36:2945-2952.
18. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerase by its 5′-triphosphate. Cancer Res. 1991;51:2386-2394.
19. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′- deoxyadenosine. Proc Natl Acad Sci USA. 1992;89:2970-2974.
20. Reichelova V, Liliemark J, Albertioni F. Liquid chromatographic study of acid stability of 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, 2-chloro-2′-deoxyadenosine and related analogues. J Pharm Biomed Anal. 1995;13:711-714.
21. Parker WB, Shaddix SC, Rose LM, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-b-D-ribofuranosyl) adenine, 2-chloro-9-(2-deoxy-2, 2-difluoro-b-D-ribofuranosyl) adenine in CEM cells. Mol Pharmacol. 1999;55:515-520.
22. Takahashi T, Kanazawa J, Akinaga S, et al. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol. 1999;43:233-240.
23. Lofti K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res. 1999;5:2438-2444.
24. Parker WB, Bapat AR, Shen JX, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribunucleotide reductase. Mol Pharmacol. 1988;34:485-491.
25. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deocy-2- fluoro-β-D-arabinofuranosyl) adenine in human lymphoblastoid cells. Cancer Res. 1995;55:2847-2852.
26. Xie KC, Plunkett W. Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reducatase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-b-D-arabinofuranosyl) adenine. Cancer Res. 1996;56:3030-3037.
27. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7:3580-3589.
28. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther. 1991;49:239-268.
29. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21:1167-1173.
30. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003;9:6335-6342.
31. Waud WR, Schmid SM, Montgomery JA, Secrist JA III. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl) adenine (Cl-F-Ara-A). Nucleosides Nucleotides Nucleic Acids. 2000;19:447-460.
32. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. In: Giaccone G, Schilsky R, Sondel P, editors. Cancer chemotherapy and biologic response modifiers, annual 19. Amsterdam: Elsevier Science BV, 2001:21-45.
33. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemias. Blood. 2004;103:784-789.
34. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379-2386.
35. Foran J, Wetzler M, Kantarjian HM, et al. A Phase II, open-label study of CLOFAREX™ in adult patients with refractory or relapsed acute myelogenous leukemia. Blood. 2002;100:271b.
36. Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically-directed ara-C therapy for refractory leukemia. Semin Oncol. 1985;12(Suppl 3):20-30.
37. Estey E, Plunkett W, Dixon D, et al. Variable predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia. 1987;1:580-583.
38. Gandhi V, Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells. Cancer Res. 1988;48:329-334.
39. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-124.
40. Cooper T, Agus M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005;55:361-368. Epub 2004 Oct 16.
41. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105:940-947. Epub 2004 Oct 14.
42. Godwin JE, Smith SE. Acute myeloid leukemia in the older patient. Crit Rev Oncol/Hematol. 2003;48S:S17-S26.
43. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18:809-816.
44. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670-1673.
45. Faderl S, Gandhi V, Verstovsek S, et al. Clofarabine plus cytarabine (ara-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood. 2004;104:250a.
46. Burnett AK, Russell N, Kell JW, et al. A Phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood. 2004;104:248a.
47. Faderl S, Ferrajoli A, Wierda W, et al. Phase I study of clofarabine plus idarubicin and clofarabine plus idarubicin plus cytarabine (ara-C) in patients (pts) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML). Blood. 2004;104:501a.
48. Jeha S, Razzouk B, Rytting ME, et al. Phase II trials of clofarabine in relapsed or refractory pediatric leukemia. Blood. 2004;104:196a.